Lupus Foundation of America Greater Ohio Chapter Logo
GREATER OHIO CHAPTER

Toll Free: 1 (888) NO-LUPUS
Phone: (440) 717-0183

Help Us Solve The Cruel MysteryTM

Donate To The Ohio Chapter

New Study Identifies Predictors of Successful Glucocorticoid Discontinuation in Systemic Lupus Erythematosus Treatment

by | Jan 22, 2025

Inside Lupus Research (ILR): Disease Management News

Long-term use of glucocorticoids (GCs) for the treatment of lupus is very common, however, it has also been associated with side effects like high blood pressure, diabetes, infection, and osteoporosis. A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can minimize flare risk and support the successful discontinuation of GCs in individuals with systemic lupus erythematosus (SLE).

In this multi-center, retrospective study, a cohort of 324 people with active SLE receiving GCs as part of their treatment plan were analyzed. A special focus was given to 220 people within the cohort who discontinued GC use. Researchers found that their risk of disease flare lowered when GC treatment was suspended when their disease was in remission. Their risk further reduced with each additional month their disease activity remained low, and total and severe flares were prevented in those taking HCQ. Overall, the combination of disease remission, HCQ use, and slow GC tapering reduced the likelihood of severe flare activity by as much as 50 times compared to participants who continued GC therapy. 

While discontinuing GCs can reduce damage and improve outcomes, close monitoring is required to prevent relapses. Talk to your doctor before making any changes to your treatment plan. Learn more about medications used to treat lupus.

Read the study

This post was originally published on this site

Skip to content